PubMed Health⌕ Search

PubMed · 10761147

Nonlinear multivariate regression outperforms several concisely designed neural networks on three QSPR data sets

Abstract

Neural networks (NNs) are accepted as the most powerful nonlinear technique in QSAR and QSPR modeling. However, the NN models are often very robust, containing a large number of parameters optimized during the training procedure. We have recently found (J. Chem. Inf. Comput. Sci. 1999, 39, 121-132) that the simpler nonlinear multiregression (MR) models are significantly better than the robust NNs, according to the same statistical parameters. In the present paper we investigated whether the nonlinear MR models are also better than the concisely designed NN models. Nonlinear MR models were generated in the following way. First, nonlinear terms, the 2-fold and 3-fold cross-products of initial descriptors, were calculated and added to initial descriptors. Then, the combination of two powerful techniques for descriptor selection (CROMRsel for "the best" selection and CROMRiisel for approximative, "i by i" stepwise selection) were used to detect the most important descriptors in MR models. For boiling points (BPs) of 150 alkanes the 20-descriptor MR model produced the cross-validated (CV) standard error of 2.88 K, and the best NN model (with 70-80 adjusted weights) had 3.60 K. Prediction of BPs of 50 compounds using the 17-descriptor MR model (obtained on 100 compounds) gave the standard error of 3.58 K. In the case of modeling of 243 chemical shifts CV standard errors were (in ppm) 0.89 and 1.19 with 15- and 9-descriptor MR models, respectively. The best NN models adjusted 60-90 weights and achieved 1.42 ppm. The standard error in predicting the 83 chemical shifts using the 10-descriptor MR model obtained on 160 samples was 1.25 ppm. It is also shown in this data set that the model quality depends on the scaling procedure used for transformation of the initial descriptors. In modeling the sublimation enthalpy the CV correlation coefficient was 0.97 using the best 4-descriptor MR model versus 0.93 obtained using NN with approximately 50 adjusted weights. The CV correlation coefficient in predicting the sublimation enthalpies for 21 compounds using the 4-descriptor MR model was 0.98. This is, to our knowledge, the first unambiguous result which shows a way for obtaining nonlinear MR models having better fitted, cross-validated, and predictive performances than the corresponding NN models. Moreover, the nonlinear MR models are significantly simpler than the NN models, which allows one to establish the functional relationships between the modeled property/activity and descriptors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Lucic, D Amic, N Trinajstic. 2000. Nonlinear multivariate regression outperforms several concisely designed neural networks on three QSPR data sets. https://doi.org/10.1021/ci990061k

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗